Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06730512 in healthy adults
NCT03146065Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing PF-06730512 with Placebo (2 arms). Primary endpoints: Number of Subjects With Treatment Emergent Treatment-Related Adverse Event(s) at Day 113, Number of subjects with injection site reaction(s) at Day 113 and 3 more. Started May 2017; status: completed.
02
Drugs
PF-06730512
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03146065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03146065.